Cargando…

Digital pattern recognition-based image analysis quantifies immune infiltrates in distinct tissue regions of colorectal cancer and identifies a metastatic phenotype

BACKGROUND: Several studies in colorectal cancer (CRC) indicate a relationship between tumour immune infiltrates and clinical outcome. We tested the utility of a digital pattern recognition-based image analysis (DPRIA) system to segregate tissue regions and facilitate automated quantification of imm...

Descripción completa

Detalles Bibliográficos
Autores principales:	Angell, H K, Gray, N, Womack, C, Pritchard, D I, Wilkinson, R W, Cumberbatch, M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2013
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3776996/ https://www.ncbi.nlm.nih.gov/pubmed/23963148 http://dx.doi.org/10.1038/bjc.2013.487

Ejemplares similares

Detailed analysis of inflammatory cell infiltration in colorectal cancer
por: Väyrynen, J P, et al.
Publicado: (2013)

Tumour-infiltrating inflammation and prognosis in colorectal cancer: systematic review and meta-analysis
por: Mei, Z, et al.
Publicado: (2014)

High density of FOXP3-positive T cells infiltrating colorectal cancers with microsatellite instability
por: Michel, S, et al.
Publicado: (2008)

Microsatellite instability in colorectal cancer is associated with local lymphocyte infiltration and low frequency of distant metastases
por: Buckowitz, A, et al.
Publicado: (2005)

Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer
por: Chua, W, et al.
Publicado: (2009)

PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients
por: Frattini, M, et al.
Publicado: (2007)

Beclin 1 over- and underexpression in colorectal cancer: distinct patterns relate to prognosis and tumour hypoxia
por: Koukourakis, M I, et al.
Publicado: (2010)

Tumour-infiltrating CD68+ and CD57+ cells predict patient outcome in stage II–III colorectal cancer
por: Chaput, N, et al.
Publicado: (2013)

KRAS mutations in primary tumours and post-FOLFOX metastatic lesions in cases of colorectal cancer
por: Kawamoto, Y, et al.
Publicado: (2012)

Methylation levels of LINE-1 in primary lesion and matched metastatic lesions of colorectal cancer
por: Murata, A, et al.
Publicado: (2013)

Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer
por: Souglakos, J, et al.
Publicado: (2009)

Phosphorylated protein phosphatase 2A determines poor outcome in patients with metastatic colorectal cancer
por: Cristóbal, I, et al.
Publicado: (2014)

Feasibility of proposed single-nucleotide polymorphisms as predictive markers for targeted regimens in metastatic colorectal cancer
por: Kim, J C, et al.
Publicado: (2013)

KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer
por: Spindler, K G, et al.
Publicado: (2013)

BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection
por: Schirripa, M, et al.
Publicado: (2015)

A specific cadherin phenotype may characterise the disseminating yet non-metastatic behaviour of pseudomyxoma peritonei
por: Bibi, R, et al.
Publicado: (2006)

TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy
por: Oden-Gangloff, A, et al.
Publicado: (2009)

Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer
por: Baker, J B, et al.
Publicado: (2011)

Protein biomarkers predictive for response to anti-EGFR treatment in RAS wild-type metastatic colorectal carcinoma
por: Lièvre, Astrid, et al.
Publicado: (2017)

No association of CpG island methylator phenotype and colorectal cancer survival: population-based study
por: Jia, Min, et al.
Publicado: (2016)

Prognostic implication of the CpG island methylator phenotype in colorectal cancers depends on tumour location
por: Bae, J M, et al.
Publicado: (2013)

Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant
por: Molinari, F, et al.
Publicado: (2009)

BRAF mutations, microsatellite instability status and cyclin D1 expression predict metastatic colorectal patients’ outcome
por: Saridaki, Z, et al.
Publicado: (2010)

Expression profiling of budding cells in colorectal cancer reveals an EMT-like phenotype and molecular subtype switching
por: De Smedt, Linde, et al.
Publicado: (2017)

Relationship of increased aurora kinase A gene copy number, prognosis and response to chemotherapy in patients with metastatic colorectal cancer
por: Dotan, E, et al.
Publicado: (2012)

Glutathione S-transferase M1-null genotype as risk factor for SOS in oxaliplatin-treated patients with metastatic colorectal cancer
por: Vreuls, C P H, et al.
Publicado: (2013)

Multiparameter DNA content analysis identifies distinct groups in primary breast cancer
por: Dayal, J H S, et al.
Publicado: (2013)

Low expression of γ-glutamyl hydrolase mRNA in primary colorectal cancer with the CpG island methylator phenotype
por: Kawakami, K, et al.
Publicado: (2008)

Type I collagen inhibits differentiation and promotes a stem cell-like phenotype in human colorectal carcinoma cells
por: Kirkland, S C
Publicado: (2009)

P4H9-detected molecule expression on spindle-shaped fibroblasts indicates malignant phenotype of colorectal cancer
por: Yokoyama, Shozo, et al.
Publicado: (2015)

Distinct expression pattern of the full set of secreted phospholipases A(2) in human colorectal adenocarcinomas: sPLA(2)-III as a biomarker candidate
por: Mounier, C M, et al.
Publicado: (2008)

HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients
por: Martin, V, et al.
Publicado: (2013)

Serum levels of hepatocyte growth factor and epiregulin are associated with the prognosis on anti-EGFR antibody treatment in KRAS wild-type metastatic colorectal cancer
por: Takahashi, N, et al.
Publicado: (2014)

Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer
por: Ino, Y, et al.
Publicado: (2013)

Epidermal growth factor receptor (EGFR) downstream signalling pathway in primary colorectal tumours and related metastatic sites: optimising EGFR-targeted treatment options
por: Scartozzi, M, et al.
Publicado: (2007)

KRAS mutational status affects oxaliplatin-based chemotherapy independently from basal mRNA ERCC-1 expression in metastatic colorectal cancer patients
por: Basso, M, et al.
Publicado: (2013)

Expression of pEGFR and pAKT as response-predictive biomarkers for RAS wild-type patients to anti-EGFR monoclonal antibodies in metastatic colorectal cancers
por: Harlé, A, et al.
Publicado: (2015)

Extreme assay sensitivity in molecular diagnostics further unveils intratumour heterogeneity in metastatic colorectal cancer as well as artifactual low-frequency mutations in the KRAS gene
por: Mariani, Sara, et al.
Publicado: (2017)

MicroRNA-126 and epidermal growth factor-like domain 7–an angiogenic couple of importance in metastatic colorectal cancer. Results from the Nordic ACT trial
por: Hansen, T F, et al.
Publicado: (2013)

Prognostic implications of type and density of tumour-infiltrating lymphocytes in gastric cancer
por: Lee, H E, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_9mhob53ah7vn4kv3n1qhua7m79